Abstract: The present invention relates to a positive dielectric anisotropic liquid crystal composition comprising one or more compounds of formula I and one or more compounds of formula II, and a liquid crystal display device. The liquid crystal composition disclosed by the present invention has the characteristics of positive dielectric properties, a high charge retention ratio, a low rotary viscosity, a fast response time, and especially a high transmittance, and is suitable for manufacturing a TFT-LCD with a high transmittance and a fast response.

Abstract: The present invention relates to a liquid crystal composition, a liquid crystal display element, and a liquid crystal display.

Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

Abstract: The present invention provides a liquid crystal composition comprising one or more compounds of general formula I and one or more compounds of general formula II; the liquid crystal composition of the present invention can work at very high and very low temperatures, has a very short response time and a better reliability to light and heat, and particularly exhibits no image retention or a significantly reduced image retention after a long time operation.

Abstract: Provided is a liquid crystal compound containing 2,3,4-trisubstituted benzene, a liquid crystal composition thereof, and a liquid crystal display element or a liquid crystal display comprising the liquid crystal compound or the liquid crystal composition, wherein the liquid crystal composition has a lower viscosity, can achieve a quick response, and further has a moderate dielectric anisotropy ??, a moderate optical anisotropy ?n, and high stability to heat and light. The liquid crystal display element or liquid crystal display comprising the liquid crystal composition has the properties of a wider nematic phase temperature range, an appropriate birefringence anisotropy, a very high electrical resistivity, a good ultraviolet resistant property, a high charge retention rate, a low vapor pressure etc., and particularly, the liquid crystal compound or the liquid crystal composition has the advantage of a high light transmittance.

Abstract: A method for coating a thin film in a rolling manner and a thin film coating apparatus are provided. The method includes: floating a thin film material on a liquefied material; rolling a cylindrical substrate after contacting the cylindrical substrate with the thin film material; and coating the thin film material on a surface of the cylindrical substrate by using an attraction force between the surface of the cylindrical substrate and the thin film material.

Abstract: This disclosure relates to methods of treating or preventing cancer comprising administering an effective amount of a glutamate dehydrogenase 1 inhibitor to a subject in need thereof.

Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.

Abstract: This disclosure relates to methods of treating or preventing cancer comprising administering an effective amount of a glutamate dehydrogenase 1 inhibitor to a subject in need thereof. In certain embodiments, the inhibitor has Formula I: prodrugs, derivatives, or salts thereof wherein the substituents are reported herein. In certain embodiments, the inhibitor is purpurin, derivative, or salt thereof. In certain embodiments, the inhibitor is 2-allyl-1-hydroxyanthracene-9,10-dione, prodrugs, derivatives, or salts thereof.

Abstract: This disclosure relates to methods of treating or preventing cancer comprising administering an effective amount of a glutamate dehydrogenase 1 inhibitor to a subject in need thereof. In certain embodiments, the inhibitor has Formula I: prodrugs, derivatives, or salts thereof wherein the substituents are reported herein. In certain embodiments, the inhibitor is purpurin, derivative, or salt thereof. In certain embodiments, the inhibitor is 2-allyl-1-hydroxyanthracene-9,10-dione, prodrugs, derivatives, or salts thereof.

Abstract: In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, head and neck cancer, and leukemia, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof.